Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. - Wikidata - thesis-toulmin - TriplyDB

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

http://www.wikidata.org/entity/Q34214330

about

Malignant mesothelioma Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for TRAIL and proteasome inhibitors combination induces a robust apoptosis in human malignant pleural mesothelioma cells through Mcl-1 and Akt protein cleavages Proteasome inhibitor MG132 induces apoptosis and inhibits invasion of human malignant pleural mesothelioma cells Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma Radiotherapy for malignant pleural mesothelioma Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.Depressogenic effects of medications: a review Orotate phosphoribosyltransferase is overexpressed in malignant pleural mesothelioma: Dramatically responds one case in high OPRT expression Pemetrexed Maintenance Therapy Following Bevacizumab-Containing First-Line Chemotherapy in Advanced Malignant Pleural Mesothelioma: A Case Report and Literatures Review Palliative cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion: current clinical practice or misnomer?Advances in the diagnosis, treatment and prognosis of malignant pleural mesothelioma Hedgehog Signaling in Malignant Pleural Mesothelioma Mesothelioma treatment: Are we on target? A review Malignant pleural mesothelioma: incidence, etiology, diagnosis, treatment, and occupational health Serine, glycine and one-carbon units: cancer metabolism in full circle Looking up: Recent advances in understanding and treating peritoneal carcinomatosis New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis Malignant mesothelioma of the pleura with desmoplastic histology: a case series and literature review.Development and binding mode assessment of N-[4-[2-propyn-1-yl[(6S)-4,6,7,8-tetrahydro-2-(hydroxymethyl)-4-oxo-3H-cyclopenta[g]quinazolin-6-yl]amino]benzoyl]-l-γ-glutamyl-D-glutamic acid (BGC 945), a novel thymidylate synthase inhibitor that targets BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma.MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53.Role of Akt signaling in resistance to DNA-targeted therapy The evolution of the diminishing role of extrapleural pneumonectomy in the surgical management of malignant pleural mesothelioma Pemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer (Review)Advances in anticancer immunotoxin therapy A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours Trial on refinement of early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: the TREAT protocol Gender-Specific Molecular and Clinical Features Underlie Malignant Pleural Mesothelioma Biomarkers and prognostic factors for mesothelioma Fibulin-3 as a biomarker of response to treatment in malignant mesothelioma Malignant mesothelioma: facts, myths, and hypotheses Reactive oxygen species a double-edged sword for mesothelioma Current issues in malignant pleural mesothelioma evaluation and management Guidelines for the diagnosis and treatment of malignant pleural mesothelioma Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies Molecular resistance fingerprint of pemetrexed and platinum in a long-term survivor of mesothelioma BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesothelioma Variation in drug sensitivity of malignant mesothelioma cell lines with substantial effects of selenite and bortezomib, highlights need for individualized therapy

P2860

Q21202901-CD35C85A-5C41-432E-AADE-692C04E0FD1A Q21261297-EA21B664-FD35-4E93-8BF7-5F7FDCE17905 Q23910293-BD4AC92B-FE97-4BC2-B40A-52D0E30B9C02 Q24170504-34D07ADA-6C5D-47EE-B861-5395C0CEA70B Q24243222-95548008-10A6-40DF-87AD-89DB1D300B2A Q24245556-6E89D6A1-5229-4F30-8862-673B6E35DF7C Q24628879-4F830C4A-25BC-424C-BAFE-7F0E31EC6BA0 Q24635465-9FCB4EFA-5064-427A-BA89-DA4D163BC303 Q26747641-93EBC168-9504-4E37-A53B-576E49B1B8DD Q26750670-CBC281B0-E02B-4E0F-9A7D-A8E985666D25 Q26768306-625E8CE5-05EF-4BA8-9BD2-495522CADE3A Q26787294-2971A978-C9E2-4D4D-96C3-194FB371406A Q26799894-E95D82B5-22F6-4D97-BB68-81FB9853C541 Q26800042-FDB139B5-E3A9-4A22-A2C0-30746E71EC5C Q26821919-EF848EE4-C379-44FC-BA89-62C22D977579 Q26828610-9A7C5DB1-FBFB-42E4-ADAE-768D9E0989E8 Q26849259-EEA839B2-1289-4AE0-822B-E628F908283E Q26859274-A010FA43-665C-43F1-BEBC-27266B3D3592 Q26860736-55B2592B-EEF6-4848-85E6-174FEEB009C7 Q27311380-AD771B9F-9A29-401C-86FD-396C7589DDC9 Q27678339-F21531D3-73EC-458A-9EC7-EE8AEE16460C Q27851697-F07E2AF0-57DF-4965-852F-925ECDAC38FC Q27853125-EE441F6F-A4C7-4C59-AFC7-DCABE68F5894 Q28066950-214ABF5D-9372-412C-84A8-B58FA881A99B Q28067111-398ECCC8-A6F3-4494-B4F9-4CB11A068C46 Q28081243-EEB83AEA-7F66-4D9B-9C1B-D3D20FD6A3AC Q28085551-10BF1368-F7B3-4347-BED2-A3AC88BF25E5 Q28200350-3482CF41-4447-43DB-AD18-108884921FB2 Q28209997-E51A084C-DD4F-4B7A-9FD2-7F977BC97A9C Q28384371-FA24B31D-51D7-40A6-BB16-6150149DED57 Q28387194-04F63E59-67B3-4810-8F8A-7AA3C2CC1D6F Q28389185-8D388B87-26D6-44F7-B6C6-7E8B215D956E Q28390539-588E6299-F79B-431B-84DF-A452DFB8D6FC Q28392665-F1053622-86D2-4B83-B053-8E4CEE61656E Q28393560-9C1BBB93-F3E1-4098-A2D1-56CAA9FE8204 Q28394028-BCE4043C-F7C1-445E-A230-DFD5862A432D Q28395597-ED7772E4-38FF-40E3-B6E4-585D621D1B9B Q28482133-512A2323-452F-4783-9366-32B13FFB5616 Q28533736-C9D39238-45C5-4FF3-831C-C9615CFC9DBE Q28534042-023B8486-9B92-418C-9116-CF4341D9B1DF

P2860

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

http://www.wikidata.org/entity/Q34214330

description

2003 nî lūn-bûn

@nan

2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Phase III study of pemetrexed ...... alignant pleural mesothelioma.

@ast

Phase III study of pemetrexed ...... alignant pleural mesothelioma.

@en

Phase III study of pemetrexed ...... alignant pleural mesothelioma.

@nl

type

label

Phase III study of pemetrexed ...... alignant pleural mesothelioma.

@ast

Phase III study of pemetrexed ...... alignant pleural mesothelioma.

@en

Phase III study of pemetrexed ...... alignant pleural mesothelioma.

@nl

prefLabel

Phase III study of pemetrexed ...... alignant pleural mesothelioma.

@ast

Phase III study of pemetrexed ...... alignant pleural mesothelioma.

@en

Phase III study of pemetrexed ...... alignant pleural mesothelioma.

@nl

P1433

Q34214330-640D1CDE-7C17-41AC-BEB7-904C2B283F12

P1476

Q34214330-1D3C46B5-DC9D-4E04-A85E-F044C765E8F5

P2093

Q34214330-10A162BB-6F31-4127-91CA-36748AE1D2F8

Q34214330-1BE00690-944D-4D50-BE30-8B20D3C04753

Q34214330-3666B30A-F811-4D7E-A82A-EDAC3C30C05C

Q34214330-625C8CBA-9962-4642-80EF-CDF65D803CC0

Q34214330-640B1053-449F-4922-B3E6-8225669B8D0D

Q34214330-7EBE8231-30AC-4C4E-8ACE-C1136047D95E

Q34214330-88B5E3C9-0372-45E8-9884-C7E83F125725

Q34214330-8DCAF0A8-A940-4476-8827-3A4C27E9FBD7

Q34214330-ACD8714E-E413-4F91-8B40-A4240739F30A

Q34214330-D2B65322-6B98-4E8A-B0CF-9FC3BBC4B504

P304

Q34214330-7979B8D4-BE6D-43D0-A301-29F1FBD8E68C

P31

Q34214330-AD28B7A8-03D8-4A4A-ACEC-2F71870D771F

P356

Q34214330-5A77905C-4302-44EB-A88C-B3ACC7C817F7

P407

Q34214330-601AC1DA-C1A0-4372-B79E-8B1108B00888

P433

Q34214330-BF533186-533F-412A-9BD9-0E76584A1C34

P478

Q34214330-C949B5EE-42CD-4A5C-B27E-466F4659F209

P577

Q34214330-EAC6B03E-0B65-4F31-AB7D-2F419F4B322F

P698

Q34214330-7F60705F-36B6-4D62-BB54-70B153641F4A

P921

Q34214330-810818B4-B3B8-4CB2-B1D4-243B8D22F579

P356

JCO.2003.11.136

P1433

Journal of Clinical Oncology

P1476

Phase III study of pemetrexed ...... alignant pleural mesothelioma.

@en

P2093

Christian Manegold

http://www.w3.org/2001/XMLSchema#string

Claude Denham

http://www.w3.org/2001/XMLSchema#string

Clet Niyikiza

http://www.w3.org/2001/XMLSchema#string

E Kaukel

http://www.w3.org/2001/XMLSchema#string

James J Rusthoven

http://www.w3.org/2001/XMLSchema#string

James Symanowski

http://www.w3.org/2001/XMLSchema#string

Michael Boyer

http://www.w3.org/2001/XMLSchema#string

Nicholas J Vogelzang

http://www.w3.org/2001/XMLSchema#string

Paolo Paoletti

http://www.w3.org/2001/XMLSchema#string

Pierre Ruffie

http://www.w3.org/2001/XMLSchema#string

P304

2636-2644

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2003.11.136

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2003-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12860938

http://www.w3.org/2001/XMLSchema#string

P921